Chromatin-targeted drug discovery at “a very special moment”

IF 101.8 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nature Reviews. Drug Discovery Pub Date : 2024-06-11 DOI:10.1038/d41573-024-00096-2

Asher Mullard

引用次数: 0

Abstract

Cigall Kadoch, a cancer researcher at Dana-Farber Cancer Institute and co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs, targeting chromatin remodelling complexes. Cigall Kadoch, a cancer researcher at Dana-Farber Cancer Institute and co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs, targeting chromatin remodelling complexes.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

处于 "非常特殊时刻 "的染色质靶向药物发现

Dana-Farber 癌症研究所癌症研究员、Foghorn Therapeutics 公司联合创始人 Cigall Kadoch 讨论了新一轮以染色质重塑复合物为靶点的表观遗传药物的案例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.

期刊最新文献

Dose-finding and optimization in drug development for rare diseases. The therapeutic potential of orphan adhesion G-protein-coupled receptors. Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate. Approvals by the China NMPA in 2025. PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.